Who
Aharon Schwartz
Director
Company insider
Files Form 4 as: Director, Protalix BioTherapeutics, Inc. (DE); Director, Foamix Pharmaceuticals.
In numbers
- Trades disclosed
- 24
- Buys
- 6
- Sells
- 0
- Bought
- $956K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 8 May 2018
- Last trade
- 3 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 9 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 3 Sep 2026filed 9 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 3 Sep 2026filed 9 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 3 Sep 2026filed 9 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 3 Sep 2025filed 4 Sep 2025 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Sep 2025filed 4 Sep 2025 | PLX Protalix BioTherapeutics, Inc. (DE)Biotechnology | SEC FORM 4 Code A | —7,500 | filing |
| 10 Jun 2025filed 12 Aug 2025 | PLX Protalix BioTherapeutics, Inc. (DE)Biotechnology | SEC FORM 4 Bought | $206K129,000 at $1.60 | filing |
| 29 Sep 2023filed 3 Oct 2023 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —61,676 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | PLX Protalix BioTherapeutics, Inc. (DE)Biotechnology | SEC FORM 4 Bought | $156K110,000 at $1.42 | filing |
| 7 Sep 2022filed 9 Sep 2022 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Apr 2020filed 13 Apr 2020 | PLX Protalix BioTherapeutics, Inc. (DE)Biotechnology | SEC FORM 4 Bought | $156K64,000 at $2.43 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —24,000 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —21,435 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —24,883 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —49,412 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —38,156 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticals | SEC FORM 4 Code D | —112,200 | filing |
| 27 Feb 2020filed 3 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —38,156 at $0.00 | filing |
| 20 Jan 2020filed 22 Jan 2020 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 May 2019filed 20 May 2019 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —49,412 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.